«Clinically silent» somatotropinoma

Lipatenkova A.K., Dzeranova L.K., Pigarova E.A.,
Endocrinology Research Centre, Moscow, Russia

Introduction

Somatotropinomas are typically recognized when GH excessively secretion causes acromegaly. «Silent» somatroph adenomas (immunohistochemical evidence of GH excess without biochemical or clinical evidence) and «clinically silent» somatotroph adenomas (immunohistochemical and biochemical evidence without clinical evidence) is unknown.

The aim

to describe the clinical course of a patient with «clinically silent» somatotroph adenoma.

Case presentation

In a female patient disease presented at the age of 22 years with oligomenorrhea and hyperprolactinemia - PRL 881.37 mU/l (127-637) for which she received cabergoline 0.25 mg per week with induction of normoprolactinemia and normalization of menstrual cycle. Within a year MRI revealed endo-suprasellar pituitary adenoma 16*15*13 mm, without chiasm compression. The levels of TSH, cortisol, LH, FSH, prolactin were in normal ranges. These changes were regarded as nonfunctioning pituitary adenoma and annual follow-up was recommended.

Subsequent MRIs showed an enlargement (21*18*17 mm), mainly due to suprasellar component without chiasm involvement (pic.1) ACTH, cortisol, PRL, LH, FSH were within reference ranges and a decrease of free T4 8.1 pmol/l (9-20) and IGF-1 elevation 816.9 ng/ml (128-315) were noted. The high fasting GH levels confirmed biochemical acromegaly (9.1-6.3-11.3-11.1-13.3 ng/ml) as at physical examination there were no clinical signs of this disease. Patient got levothyroxine 25 mg a day to correct secondary hypothyroidism.

Conclusions:
Clinically silent somatotroph adenomas with biochemical and immunohistochemical evidence of growth hormone excess but absence of clinical features of acromegaly were first described nearly 30 years ago. There were no significant biochemical or histological differences between clinically active and clinically silent somatotroph adenomas. This case demonstrates the need to perform an extensive hormonal testing for all patients with presumably non-active pituitary adenoma.

Contact author – a.lipatenkova@gmail.com